Sun Pharmaceutical Industries has responded to rumors regarding a potential acquisition of Organon for USD 10 Billion. The company stated that the information circulating in the news is speculative and does not represent any material event requiring disclosure. Sun Pharma assures adherence to high governance standards and will keep stock exchanges informed of any material events as required.
Response to Market Rumors
Sun Pharmaceutical Industries has addressed recent speculation concerning a potential acquisition. The company responded to an email dated January 19, 2026, regarding news of a potential USD 10 Billion acquisition of Organon.
Company Statement
Sun Pharma has clarified that the information in the mentioned article is speculative. The company emphasized that this news does not contain information that requires mandatory disclosure. Sun Pharma reiterated its commitment to maintaining high standards and transparency.
Source: BSE
